CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT-REPORTED OUTCOMES MULTICOHORT STUDY

被引：0
|
作者：
Marques, R. P. [1 ]
Heudtlass, P. [2 ]
Godinho, A. R. [2 ]
Pais, H. L. [1 ]
Quintela, A. [1 ]
Lopes, da Cruz J. P. [1 ]
Martins, A. P. [3 ]
机构：
[1] Ctr Hosp Univ Lisboa Norte, Lisbon, Portugal
[2] Ctr Hlth Evaluat & Res, Lisbon, Portugal
[3] Univ Lisbon, Fac Pharm, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN18
引用
下载
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [41] The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Yuying Cui
    Yingxue Guo
    International Journal of Clinical Pharmacy, 2022, 44 : 843 - 851
  • [42] The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Cui, Yuying
    Guo, Yingxue
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (04) : 843 - 851
  • [43] Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis
    Yuying Cui
    Yingxue Guo
    International Journal of Clinical Pharmacy, 2024, 46 : 555 - 557
  • [44] Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Larsen, Finn Ole
    Pfeiffer, Per
    Nielsen, Dorte
    Skougaard, Kristin
    Qvortrup, Camilla
    Vistisen, Kirsten
    Fromm, Anne-Lene
    Jorgensen, Trine L.
    Bjerregaard, Jon K.
    Hoegdall, Estrid
    Jensen, Benny V.
    ACTA ONCOLOGICA, 2011, 50 (04) : 574 - 577
  • [45] PATIENT-REPORTED OUTCOMES (PRO) IN A FIRST-LINE STUDY (20060314) OF PANITUMUMAB plus FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Karthaus, M.
    Resch, G.
    Mineur, L.
    Hofheinz, R.
    Greil, R.
    Letocha, H.
    Fernebro, E.
    Gamelin, E.
    DeCosta, L.
    Koehne, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 75 - 75
  • [46] Patient-reported outcomes with metastatic castrate-resistant prostate cancer.
    Mullally, Jimmy
    Davella, Christopher
    Parikh, Rahul Atul
    Van Londen, G. J.
    Appleman, Leonard Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34)
  • [47] Exploration of Patient-Reported Outcomes (PRO) in metastatic breast cancer clinical studies
    Zhang, Lijun
    Zhou, Jiaxi
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 119 - 119
  • [48] Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Wânia Cristina da Silva
    Vânia Eloisa de Araujo
    Ellias Magalhães e Abreu Lima
    Jessica Barreto Ribeiro dos Santos
    Michael Ruberson Ribeiro da Silva
    Paulo Henrique Ribeiro Fernandes Almeida
    Francisco de Assis Acurcio
    Brian Godman
    Amanj Kurdi
    Mariângela Leal Cherchiglia
    Eli Iola Gurgel Andrade
    BioDrugs, 2018, 32 : 585 - 606
  • [49] Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    da Silva, Wania Cristina
    de Araujo, Vania Eloisa
    Lima, Ellias Magalhaes e Abreu
    Ribeiro dos Santos, Jessica Barreto
    Ribeiro da Silva, Michael Ruberson
    Ribeiro Fernandes Almeida, Paulo Henrique
    Acurcio, Francisco de Assis
    Godman, Brian
    Kurdi, Amanj
    Cherchiglia, Mariangela Leal
    Gurgel Andrade, Eli Iola
    BIODRUGS, 2018, 32 (06) : 585 - 606
  • [50] Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population
    Lamy, Francois-Xavier
    Batech, Michael
    Boutmy, Emmanuelle
    Ronga, Philippe
    Salim, Shaista
    Pescott, Chris P.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (16) : 1117 - 1129
12345